Amiri-Kordestani, Laleh <br/><br/>
FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Sep 2014 
 - 4436-41 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-14-0012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Ado-Trastuzumab Emtansine<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Drug Approval<br/>Drug-Related Side Effects and Adverse Reactions<br/>Female<br/>Humans<br/>Maytansine--administration & dosage<br/>Middle Aged<br/>Receptor, ErbB-2--genetics<br/>Trastuzumab<br/>United States<br/>United States Food and Drug Administration